China Summit Segment II: Cross-Border Outlook – Access to Capital and Partnering Strategies for the China Market

3:15 PM - 4:15 PM, Monday, June 3,2019 ・ 113ABC: Level 100
Partnerships are the life blood of research and development, as well as commercialization. As the industry becomes more global, companies must evaluate and adopt various cross-border strategic models to drive capital formation and growth. One year ago, the Hong Kong Exchange (HKEX) began to allow pre-revenue biotechnology companies to list – creating a new thriving IPO hub for innovative biopharmaceutical companies. Join us for a one-year look back on the takeaways from the HKEX listing rule, as well as discussions on investor strategies for the China market. 3:15 to 4:15pm Cross-Border Outlook: Access to Capital and Partnering Strategies for the China Market Panelists: • Jinzi J. Wu, PhD, Founder, Chairman and CEO, Ascletis Pharma Inc. • Michael Chan, Senior Vice President, Global Markets, Hong Kong Exchanges and Clearing Limited (HKEX) • Fangfang Zhu, Vice President, WI Harper Group • Yuquan Wang, Founding Partner, Haiyin Capital • Richard Matheny, Partner, Goodwin Moderator: Wendy Pan, Board of Directors, BayHelix
Speakers
photo
Senior Vice President
Hong Kong Exchanges and Clearing Limited (HKEX)
Jinzi Wu
Founder, Chairman and CEO
Ascletis Pharma Inc.
photo
Vice President
WI Harper Group
photo
Founding Partner
Haiyin Capital
photo
Partner
Goodwin